“Covid-19: A combination of early stage drugs works (hydroxychloroquine, ivermectin). New study”
The year 2020 will have been marked by a series of studies on treatments against COVID-19 and associated controversies. All will remember the declarations of the Minister of Health and the Prime Minister that ” there is no treatment against Covid-19 ” despite the studies published by the IHU of Prof. Raoult. In December, the Italian Council of State rehabilitated the early-phase treatment based on hydroxychloroquine, proving the doctors right and recalling the principle that no national agency should interfere in the privileged relationship between a doctor and his patient.
In the United States in October, under the influence of Senator Johnson , Professors Peter McCullough , Harvey Risch, and doctor Pierre Kory testified under oath to the Senate commission of inquiry into early stage treatments. The latter recalled the fundamental basis of a response to a viral epidemic with the 4 pillars: the control of contagion by various measures such as barrier gestures, early phase treatment, hospital care, and the vaccine or group immunity.
A peer-reviewed study published in the Reviews of Cardiovascular Medicine (Reviews of Cardiovascular Medicine) on December 30, 2020 by a group of 57 doctors, including Dr. Peter McCullough and Dr. Harvey Risch, many of whom have treated the disease in the early phase, includes all the elements to show that there is no cure for Covid-19, but that a combination of drugs and other supplements can significantly reduce the risk of worsening the disease . This also leads to a reduction in hospitalization needs, thus reducing the pressure on the use of intensive care or resuscitation beds. The question of risk benefit for the need for a vaccine therefore arises.
The study summary states: “The SARS-CoV-2 virus that is spreading across the world has resulted in epidemic peaks of COVID-19 disease, hospitalizations and deaths. The complex and multifaceted pathophysiology of COVID-19 is life threatening to those infected (including damage to organs mediating the virus, cytokine storm and thrombosis). This therefore justifies early interventions to treat all facets of the disease . In countries where therapeutic nihilism is prevalent, patients experience escalating symptoms and without early treatment, patients may succumb to complications of delayed hospitalization, resulting in death. Early and rapid initiation of Combination Sequence Therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and deaths.”
A multi-pronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combined intracellular anti-infective therapy, 3) inhaled / oral corticosteroids, 4) antiplatelet / anticoagulant agents, 5) supportive care, including supplemental oxygen, monitoring and telemedicine.
Randomized trials of new individual oral therapies have failed to provide doctors with the tools they need to fight the pandemic. No single treatment option so far has been fully effective and therefore a combination is required at this time. An urgent immediate transition from single drug therapy to SMDT regimens should be used as a critical strategy to treat the large number of patients with acute COVID-19 with the goal of reducing the intensity and duration of symptoms and avoiding hospitalization and death.
The risk of complications and death increases if there is no early phase treatment as soon as the first symptoms appear.
This study therefore supports the approach advocated by Professor Raoult since the start of the year: treatment in the early phase helps reduce the risk of complications linked to the disease. It also confirms all the work done in the United States by Dr. Zelenko as well as all the doctors who have worked for the early phase treatment against thick and thin, too often ignored by health agencies and medical authorities.
The ANSM (National Agency for Health and Medicines), the Minister of Health and the various administrative bodies will undoubtedly have to explain their decisions to the French. The benefit-risk analysis as described by the Italian Council of State (in the absence of specific treatment, there is no reason that health agencies interfere in the doctor-patient relationship, especially for drugs that have proven to be safe over several decades) makes sense in the light of this new study. The abandonment of hydroxychloroquine in the arm of various studies when the signs were positive (Hycovid study), overdose in other studies, media silence on ivermectin will undoubtedly need to be addressed by those with comprehensive legal expertise.